DJI
-0.63%
SPX
-0.33%
IXIC
-0.22%
FTSE
-0.38%
N225
-0.19%
AXJO
-0.11%

NRXP missed EPS expectations by 138.39%

Mar 26, 2025, 10:34 PM
0.00%
What does NRXP do
NRX Pharmaceuticals, headquartered in Wilmington, Delaware, is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, including its lead compounds NRX-100 and NRX-101. The company went public on November 20, 2017, and is developing therapies targeting bipolar depression, chronic pain, and PTSD.
NRX Pharmaceuticals (NRXP) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, NRX Pharmaceuticals's actual EPS was -$0.77, missing the estimate of -$0.32 per share, resulting in a -138.39% surprise.
📡️ Health Care
Earnings Surprise

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

© 2024 Cashu PTY LTD.